lansoprazole has been researched along with Gastrointestinal Hemorrhage in 29 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe a case of thrombocytopenia associated with the administration of lansoprazole." | 7.71 | Lansoprazole-induced thrombocytopenia. ( Anderson, CG; Zlabek, JA, 2002) |
| "To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use." | 5.27 | Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. ( Ashida, K; Funao, N; Kawai, T; Mizokami, Y; Nishimura, A; Oda, K; Soen, S; Sugano, K, 2018) |
| "Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study." | 5.27 | Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. ( Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K, 2018) |
| ", omeprazole, misoprostol, and high-dose famotidine) in the prevention of NSAID-induced gastroduodenal ulcers will also be effective in this setting." | 3.71 | Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. ( Lanas, AI, 2001) |
| "To describe a case of thrombocytopenia associated with the administration of lansoprazole." | 3.71 | Lansoprazole-induced thrombocytopenia. ( Anderson, CG; Zlabek, JA, 2002) |
| "His only medical history was mild Alzheimer's disease diagnosed 6 months prior." | 2.52 | Upper gastrointestinal bleed associated with cholinesterase inhibitor use. ( Kok, KS; Loke, Y; Southgate, J, 2015) |
| "lansoprazole was 0." | 1.91 | Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan. ( Deguchi, H; Fernandez, J; Igarashi, A; Ishii, M; Kawai, T; Suzuki, M; Tsujita, K, 2023) |
| "Omeprazole treatment did not result in mucosal injury or inflammation; however, there were marked shifts in numbers and types of enteric bacteria, including a significant reduction (∼80%) of jejunal Actinobacteria and Bifidobacteria spp." | 1.37 | Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. ( Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL, 2011) |
| "(1) The majority of trauma admissions are at high risk for developing gastrointestinal haemorrhage." | 1.36 | Gastroprotection in trauma patients receiving non-steroidal anti-inflammatory drugs. ( Chan, JK; Graham, A; Phoenix, G; Sharma, S; Sleat, G, 2010) |
| "Lansoprazole was more potent than omeprazole, famotidine and ranitidine in inhibiting gastric mucosal lesions and hemorrhagic shock- or stress-induced bleeding." | 1.29 | [Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion]. ( Asano, S; Inada, I; Inatomi, N; Murakami, I; Satoh, H, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 8 (27.59) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, M | 1 |
| Kawai, T | 3 |
| Tsujita, K | 1 |
| Igarashi, A | 1 |
| Suzuki, M | 1 |
| Deguchi, H | 1 |
| Fernandez, J | 1 |
| Páramo-Zunzunegui, J | 1 |
| Ortega-Fernandez, I | 1 |
| Benito-Barbero, S | 1 |
| Rubio-López, L | 1 |
| Parton, JR | 1 |
| Ritchie, J | 1 |
| Mizokami, Y | 2 |
| Oda, K | 2 |
| Funao, N | 2 |
| Nishimura, A | 2 |
| Soen, S | 1 |
| Ashida, K | 2 |
| Sugano, K | 2 |
| Matsumoto, Y | 1 |
| Ishido, K | 1 |
| Tanabe, S | 1 |
| Azuma, M | 1 |
| Katada, C | 1 |
| Wada, T | 1 |
| Yano, T | 1 |
| Koizumi, W | 1 |
| Oe, S | 1 |
| Watanabe, T | 1 |
| Kume, K | 1 |
| Shibata, M | 1 |
| Hiura, M | 1 |
| Yoshikawa, I | 1 |
| Harada, M | 1 |
| Bennett, C | 1 |
| Klingenberg, SL | 2 |
| Langholz, E | 2 |
| Gluud, LL | 2 |
| Kok, KS | 1 |
| Loke, Y | 1 |
| Southgate, J | 1 |
| Lin, PY | 1 |
| Tang, JH | 1 |
| Chang, CC | 1 |
| Chatterjee, S | 1 |
| Couto, G | 1 |
| Bispo, M | 1 |
| Barreiro, P | 1 |
| Monteiro, L | 1 |
| Matos, L | 1 |
| Bretagne, JF | 1 |
| Chan, JK | 1 |
| Sleat, G | 1 |
| Sharma, S | 1 |
| Phoenix, G | 1 |
| Graham, A | 1 |
| Brophy, GM | 1 |
| Brackbill, ML | 1 |
| Bidwell, KL | 1 |
| Brophy, DF | 1 |
| Wallace, JL | 1 |
| Syer, S | 1 |
| Denou, E | 1 |
| de Palma, G | 1 |
| Vong, L | 1 |
| McKnight, W | 1 |
| Jury, J | 1 |
| Bolla, M | 1 |
| Bercik, P | 1 |
| Collins, SM | 1 |
| Verdu, E | 1 |
| Ongini, E | 1 |
| Imaeda, H | 1 |
| Hosoe, N | 1 |
| Suzuki, H | 1 |
| Saito, Y | 1 |
| Ida, Y | 1 |
| Nakamura, R | 1 |
| Iwao, Y | 1 |
| Ogata, H | 1 |
| Hibi, T | 1 |
| Lim, YJ | 1 |
| Phan, TM | 1 |
| Dial, EJ | 1 |
| Graham, DY | 1 |
| Lichtenberger, LM | 1 |
| Agustí-Escasany, A | 1 |
| Vallano-Ferraz, A | 1 |
| Inatomi, N | 3 |
| Nitta, K | 1 |
| Sakurai, Y | 1 |
| Aoki, T | 1 |
| Michel, P | 1 |
| Duhamel, C | 1 |
| Bazin, B | 1 |
| Raoul, JL | 1 |
| Person, B | 1 |
| Bigard, MA | 1 |
| Legoux, JL | 1 |
| Sallerin, V | 1 |
| Colin, R | 1 |
| Murakami, I | 2 |
| Asano, S | 2 |
| Inada, I | 1 |
| Satoh, H | 2 |
| Yukishige, K | 1 |
| Nagaya, H | 1 |
| Howden, CW | 1 |
| Lanas, AI | 1 |
| Hawkey, GM | 1 |
| Cole, AT | 1 |
| McIntyre, AS | 1 |
| Long, RG | 1 |
| Hawkey, CJ | 1 |
| Zlabek, JA | 1 |
| Anderson, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452750] | Phase 3 | 642 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456260] | Phase 3 | 406 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452763] | Phase 3 | 621 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456247] | Phase 3 | 439 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| The Role of Tranexamic Acid for the Treatment of Gastrointestinal Bleeding: A Randomized Double-blind Controlled Trial[NCT03540368] | 336 participants (Anticipated) | Interventional | 2018-07-04 | Suspended (stopped due to increased number of patients death) | |||
| Tranexamic Acid to Prevent Bleeding After Endoscopic Resection of Large Colorectal Polyps: A Pilot Project[NCT04559880] | Phase 4 | 25 participants (Actual) | Interventional | 2020-09-10 | Active, not recruiting | ||
| Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial[NCT02903017] | Phase 4 | 114 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for lansoprazole and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Upper gastrointestinal bleed associated with cholinesterase inhibitor use.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Duodenal Ulcer; Endoscop | 2015 |
[Prevention of GI bleeding due to antiplatelet agents: a labyrinth!].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Comb | 2009 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents | 2012 |
[Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Gastric Acid; Gastric Mucosa; G | 2008 |
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 1999 |
8 trials available for lansoprazole and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Comparison of oral and intravenous lansoprazole for the prevention of bleeding from artificial ulcers after endoscopic submucosal dissection for gastric tumors: a prospective randomized phase II study (KDOG 0802).
Topics: Administration, Oral; Aged; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; Hemos | 2018 |
Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Critical Illness; Famotidine; Fem | 2010 |
Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost-Benefit An | 2011 |
Intravenous administration of lansoprazole: a preliminary study of dose ranging and efficacy in upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1995 |
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1994 |
Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifibrinolytic Agents; Blood Transfusi | 2001 |
15 other studies available for lansoprazole and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Esomeprazole; Gastrointestinal Hemorr | 2023 |
Eosinophilic colitis: an infrequent disease with difficult diagnose.
Topics: Aged, 80 and over; Biopsy; Colitis; Colon; Colonoscopy; Cromolyn Sodium; Drug Therapy, Combination; | 2020 |
Acute upper gastrointestinal bleed in the puerperium following weight reduction surgery.
Topics: Acute Disease; Adult; Bariatric Surgery; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; I | 2020 |
A case of idiopathic gastroesophageal submucosal hematoma and its disappearance observed by endoscopy.
Topics: Aged; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophageal Diseases; Esophagogastric Junction; | 2014 |
A rare cause of GI bleeding in a 56-year-old man.
Topics: Anti-Ulcer Agents; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Middle Aged; Mucormycosi | 2017 |
Watermelon stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Follow-Up Studies; Gastric Antral Vascular Ectasia; G | 2008 |
Unique endoscopy findings in collagenous colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2009 |
Gastroprotection in trauma patients receiving non-steroidal anti-inflammatory drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2010 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis | 2012 |
[Gastric protection and treatment with low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
[Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Animals; Anti-Ulcer Agents; Famotidine; Gast | 1996 |
[Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Dru | 1996 |
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
Lansoprazole-induced thrombocytopenia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Gastrointestina | 2002 |